Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis

INTRODUCTION: Patients with psoriatic arthritis (PsA) who receive an initial tumor necrosis factor inhibitor (TNFi) may switch to another TNFi or a non-TNFi biologic therapy. This study compared the healthcare resource use (HRU), expenditures, and time to discontinuation among TNFi-experienced patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Betts, Keith A., Lu, Yichen, Singh, Rakesh, Clewell, Jerry, Griffith, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514202/
https://www.ncbi.nlm.nih.gov/pubmed/31055779
http://dx.doi.org/10.1007/s40744-019-0158-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514202/
https://www.ncbi.nlm.nih.gov/pubmed/31055779
http://dx.doi.org/10.1007/s40744-019-0158-2

Ejemplares similares